Last update: Nov. 24, 2016

Панкрелипаза

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

Proteolytic and lipolytic enzyme which is derived from mammalian pancreas that has protease, lipase and amylase activity. Indicated for treatment of cystic fibrosis and chronic pancreatitis.

At latest update no published data on excretion into breast milk was found.

Its high molecular weight and poor intestinal absorption make it highly unlikely a significant passage to the milk.
A low oral bioavailability hinders the passage into infant plasma from ingested milk.

It is a medication used in children and young infants.

Alternatives

We do not have alternatives for Панкрелипаза since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Панкрелипаза is Pancreatin in Cyrillic.

Is written in other languages:

Панкрелипаза is also known as

Group

Панкрелипаза belongs to this group or family:

Tradenames

Main tradenames from several countries containing Панкрелипаза in its composition:

Pharmacokinetics

Variable Value Unit
Bioavailability 0 %
Molecular weight 43.000 - 50.000 daltons
Tmax 0,5 hours
T1/2 3 hours

References

  1. BGP. Pancreatine. Product Monograph. 2014 Full text (in our servers)
  2. AEMPS. Pancreatina. Ficha técnica. 2012 Full text (in our servers)
  3. Colombo C, Fredella C, Russo MC, Faelli N, Motta V, Valmarana L, Longo L, D'Orazio C. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. Pancreas. 2009 Abstract

Total visits

717

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child's Health in Greece

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM